I
InnoRNA
Proprietary LNP platform for effective mRNA delivery, enabling advanced nucleic acid therapeutics
About InnoRNA
Innorna, established in 2019, is a pioneering company that specializes in the research and development of a delivery platform for nucleic acid therapeutics, specifically mRNA (messenger RNA) technologies. mRNA is a type of RNA that carries genetic information from DNA to the ribosome, where it specifies the sequence of amino acids to make a protein. Innorna's business operates in the biotechnology and pharmaceutical market, serving clients who require innovative solutions for disease treatment and prevention.
Read full description
The company's unique selling point lies in its proprietary LNP (Lipid Nanoparticle) and mRNA technologies. These technologies are designed to safely and effectively deliver mRNA into the correct cells, a challenge that has long plagued the industry. By overcoming this hurdle, Innorna has unlocked the potential of mRNA as a therapeutic tool, guiding cells to produce proteins that combat diseases.
Innorna's business model revolves around the commercialization of this groundbreaking technology. The company has filed 34 invention patents globally, protecting its innovative LNP and mRNA platforms. Through the rational design and optimization of mRNA sequences, Innorna has identified optimal ribosome-binding sequences, enabling more efficient and long-lasting protein translation. This has allowed the company to develop a diversified portfolio of mRNA medicine pipelines, offering a wide range of potential prophylactic and therapeutic strategies.
In terms of revenue generation, Innorna likely profits from the licensing of its patented technologies, partnerships with other biotech and pharmaceutical companies, and the sale of its mRNA therapeutic products.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Shenzhen, China
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 54.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2022 | $120M | $480M | Fangyuan Capital · CDH Investments · CPE · Huaxing Healthcare Fund | ↗ |
| SPINOUTOther financing | Jan 2019 | $0 | — | Karolinska Institute | — |
Growth signals
Latest recorded traffic for InnoRNA is 1.9K monthly website visits, up 26.7% over the last three months. InnoRNA's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CDH Investments- HFHuaxing Healthcare Fund
- FCFangyuan Capital
CPE
Other known investors1 additional known investor
Karolinska Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InnoRNA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InnoRNA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.